Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OphthalmoPharma Ltd.

www.ophthalmopharma.com

Latest From OphthalmoPharma Ltd.

Start-Up Quarterly Statistics, Q3 2011

Biopharma start-ups raised $299 million and just over half were Series A rounds. Device companies brought in $134 million, while two diagnostics firms raised $10 million total. Ophthalmology was the most popular theracat for biopharma alliances. Just one acquisition involving a start-up took place.

BioPharmaceutical Medical Device

Altacor to evaluate lead compound from Proximagen's 5HT2c programme for glaucoma

The UK specialty ophthalmic pharma company, Altacor Limited, has entered into a collaborative agreement with Proximagen to research and develop PRX00933 – the lead compound from Proximagen's 5HT2c programme acquired as part of the acquisition of Cambridge Biotechnology – as a treatment for glaucoma. Altacor also has the option for exclusive, global rights to develop the candidate in all ophthalmic indications.

Metabolic Disorders Gynecology & Urology

Deals Shaping the Medical Industry (09/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology

The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • OphthalmoPharma Ltd.
  • Senior Management
  • Patrik Frei, Chmn.
  • Contact Info
  • OphthalmoPharma Ltd.
    Phone: (41) 41 670 1887
    Bahnhofplatz 5
    Sarnen, CH 6060
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register